fls.txt



item1.txt
See notes to unaudited condensed consolidated financial statements.
See notes to unaudited condensed consolidated financial statements.
The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q.
The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature.
The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”).
2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less.
Approximately 36% and 49% of net sales of Benchtop Laboratory Equipment for the three month periods ended September 30, 2019 and 2018, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.
Approximately 33% and 25% of total Benchtop Laboratory Equipment sales were derived from the Torbal Scales Division for the three months ended September 30, 2019 and 2018, respectively.
For the three months ended September 30, 2019 and 2018, respectively, three customers accounted for approximately 23% (both periods) of net sales of the Benchtop Laboratory Equipment Operations (18% and 19% of the Company’s total revenues).
Sales to two customers during the three months ended September 30, 2019 accounted for approximately 90% of the Catalyst Research Instruments Operations revenues and 6% of the Company’s total revenues.
Sales to three customers during the three months ended September 30, 2018 accounted for approximately 83% of the Catalyst Research Instrument Operations’ revenues and 9% of the Company’s total revenues.
The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
Level 2 - Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.
The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments.
The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.
The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following tables.
Total amortization expense was $19,500 and $61,000 for the three months ended September 30, 2019 and 2018, respectively.


item2.txt
Item 2.
Overview.
The Company reflected a loss before income tax expense of $75,700 for the three months ended September 30, 2019 compared to income before tax expense of $177,500 for the three months ended September 30, 2018, primarily from the result of decreased revenues and gross margins for the Benchtop Laboratory Equipment Operations resulting from reduced orders from Asia, primarily China, and increased component costs as a result of tariffs imposed.
Sales of Catalyst Research Instruments decreased by $78,800 to $138,700 for the three months ended September 30, 2019 compared to $217,500 for the three months ended September 30, 2018 due to low order input during the period.
The gross profit percentage on a combined basis was 48.9% for the three months ended September 30, 2019 compared to 46.4% for the three months ended September 30, 2018.
Selling expenses for the three months ended September 30, 2019 increased $73,000 (30.9%) to $309,100 from $236,100 for the three months ended September 30, 2018 primarily due to increased market research and marketing activities by the Bioprocessing Systems Operations, and to a lesser extent increased marketing by the Benchtop Laboratory Equipment Operations.
Research and development expenses increased by $119,200 (101.5%) to $236,600 for the three months ended September 30, 2019 compared to $117,400 for the three months ended September 30, 2018, mainly due to the ramp up in product development activities by the Bioprocessing Systems Operations which included staffing and materials.
As a result of the foregoing, the Company recorded a net loss of $56,200 for the three months ended September 30, 2019 compared to net income of $142,000 for the three months ended September 30, 2018.
Net cash used in operating activities was $324,100 for the three months ended September 30, 2019 compared to net cash provided by operating activities of $460,700 during the three months ended September 30, 2018, primarily as a result of the loss incurred for the current year period.


